Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

Background Vedolizumab (VDZ) was approved by the Japanese Ministry of Health, Labor and Welfare in 2018 for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The comparative cost-effectiveness of VDZ compared with other biologics is unknown in Japan. This information...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2020-01, Vol.38 (1), p.69-84
Hauptverfasser:	Hernandez, Luis, Kuwabara, Hiroyo, Shah, Anshul, Yamabe, Kaoru, Burnett, Heather, Fahrbach, Kyle, Koufopoulou, Maria, Iwakiri, Ryuichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Biological products Biological response modifiers Comparative analysis Cost analysis Cost control Crohn's disease Decision trees Drug therapy Economic aspects Health Administration Health care policy Health Economics Health technology assessment Inflammatory bowel disease Medical care, Cost of Medical treatment Medicine Medicine & Public Health Monoclonal antibodies Original Original Research Article Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Reimbursement Remission (Medicine) Surgery Systematic review Testing Tumor necrosis factor-TNF Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!